Learning Dynamics: Atomoxetine Study

We are investigating how a low dose of atomoxetine affects learning and emotional states in healthy adults. This study aims to understand its impact on learning tasks and emotional well-being.

>2 years≤5 visitsEfficacy phase (II)Standard MedicinesOralPsychiatry

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Atomoxetin Stada
Atomoxetin Stada is a medicine that helps improve attention and reduce hyperactivity in people with ADHD.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Atomoxetine
Atomoxetine is a substance that helps improve attention and reduce impulsivity and hyperactivity in people with attention deficit hyperactivity disorder.
Gelatin
Gelatin is a substance used in capsules and tablets as a binder and gelling agent.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Agakalin
Atama
Atamax

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
Institut de Neuromodulation
Maison Blanche, France
Sponsor: Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.